🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

RecruitingNAAges 18 Years - anyAllThomas Jefferson University
NCT05502523 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC * Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease Exclusion Criteria: * Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment). * Preoperative chemotherapy, immunotherapy, or radiation therapy * Receipt of perioperative blood transfusion
💊

What it tests

  • Pulmonary Artery-First Surgical Technique
  • Biospecimen Collection
📍

Where

4 sites
Abington Memorial Hospital
Abington, United States
Jefferson Health Northeast
Philadelphia, United States
Thomas Jefferson University Hospital
Philadelphia, United States
Asplundh Cancer Pavilion at Jefferson Health
Willow Grove, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy